Gonococcal proctitis is an infection of the rectum caused by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. It ranks among the most common sexually transmitted rectal infections worldwide, and the majority of cases produce no symptoms at all, meaning most people who have it don’t know unless they’re specifically tested. That silent nature makes it both a clinical challenge and a public health concern, particularly because untreated rectal gonorrhea can facilitate the transmission of other infections, including HIV.
Who Gets It and How
Gonococcal proctitis occurs in anyone who has receptive anal exposure to the bacterium. It is most frequently diagnosed in men who have sex with men, but it can affect anyone engaging in receptive anal intercourse or, less commonly, through contiguous spread from a nearby genital infection. European guidelines identify Neisseria gonorrhoeae, along with Chlamydia trachomatis, herpes simplex virus, and Treponema pallidum, as the most common sexually transmitted anorectal pathogens.
Transmission happens through direct mucosal contact during anal sex. Interestingly, the type of lubricant used may influence risk. A cross-sectional study of men who have sex with men found that using a partner’s saliva as a lubricant for anal sex roughly doubled the odds of rectal gonorrhea after adjusting for other risk factors.1PubMed. Saliva use as a lubricant for anal sex is a risk factor for rectal gonorrhoea among men who have sex with men, a new public health message: a cross-sectional survey A separate study looking at lubrication practices and receptive anal sex confirmed that spit or saliva lubricant use was associated with a positive rectal STI result.2PubMed Central. Lubrication Practices and Receptive Anal Sex: Implications for STI Transmission and Prevention The likely mechanism is straightforward: saliva can harbor pharyngeal gonorrhea, which is often asymptomatic, so using it as a lubricant introduces the bacterium directly to the rectal mucosa.
Partner concordance rates for gonorrhea are high. In a study of sexual partnerships where one partner had gonorrhea or co-infection with gonorrhea and chlamydia, over half of the partners tested positive for gonorrhea or chlamydia themselves.3PubMed Central. The Prevalence of Chlamydia, Gonorrhea, and Trichomonas in Sexual Partnerships: Implications for Partner Notification and Treatment This underscores why partner notification and treatment remain central to controlling spread.
Why Most Cases Are Silent
The most important thing to understand about gonococcal proctitis is that the majority of rectal gonorrhea infections cause no symptoms. European clinical guidelines state plainly that most rectal gonococcal infections are asymptomatic and can only be detected by laboratory tests.4PubMed Central. Infectious proctitis: what every gastroenterologist needs to know A prospective study tracking rectal STIs in men who have sex with men found that only about 30% of incident rectal gonorrhea infections produced any rectal symptoms at all.5Open Forum Infectious Diseases. Prevalence, Duration, and Severity of Rectal Symptoms Among Men Who Have Sex With Men With Rectal Sexually Transmitted Infections
When symptoms do appear, they typically develop about a week and a half after infection and last around a week. The classic presentation includes rectal discharge (which may be purulent or mucoid), anorectal pain, tenesmus (the sensation of needing to pass stool without being able to), and occasionally rectal bleeding. Some people experience itching or a vague sense of rectal fullness. These symptoms overlap heavily with other causes of proctitis, including chlamydia, herpes, and syphilis, so symptoms alone cannot tell you the cause.
The high rate of asymptomatic infection is what makes routine screening so important. Someone who feels perfectly fine can still transmit the infection to partners and remain at elevated risk for complications, including increased susceptibility to HIV.
Diagnosis Has Changed Dramatically
For decades, culture was the standard method for detecting rectal gonorrhea, and it missed a lot of infections. Nucleic acid amplification tests have transformed diagnosis. One study directly comparing culture with modern testing methods found that culture sensitivity for rectal gonorrhea ranged from about 67% to 72%, while the most sensitive amplification test achieved 100% sensitivity.6PubMed Central. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections In practical terms, culture was missing roughly a third of rectal gonorrhea cases that amplification testing could catch.
A real-world transition study confirmed the clinical impact: when a sexual health clinic switched from culture to amplification testing, the proportion of tests positive for rectal gonorrhea doubled, from about 4% to 8%.7Sexually Transmitted Diseases. Increased Detection of Pharyngeal and Rectal Gonorrhea in Men Who Have Sex With Men After Transition From Culture To Nucleic Acid Amplification Testing The infections had always been there; older testing methods simply couldn’t find them. This shift in diagnostic technology has reshaped our understanding of how common extragenital gonorrhea truly is and raised awareness that treatment failures at rectal and pharyngeal sites may be more frequent than at genital sites.8Clinical Infectious Diseases. A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned
A multicenter comparison of several commercial amplification assays confirmed that, despite some variation in sensitivity between different platforms, these tests consistently outperform culture for detecting extragenital infections.9PubMed Central. Multicenter Comparison of Nucleic Acid Amplification Tests for the Diagnosis of Rectal and Oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae Infections
Self-Collected Swabs Work Well
One barrier to rectal STI screening has always been the clinic visit itself. Many people find rectal examinations uncomfortable or embarrassing, and access to sexual health clinics varies widely. Self-collected rectal swabs offer a way around this. A study comparing at-home self-swabs to clinician-collected specimens found that at-home rectal swabs for gonorrhea testing achieved 100% sensitivity and over 99% specificity.10PLoS ONE. Testing for extragenital Neisseria gonorrhoeae and Chlamydia trachomatis: At-home pharyngeal and rectal self-swabs are non-inferior to those completed in healthcare settings In other words, self-swabbing at home caught every case of rectal gonorrhea that a clinician-collected swab would have found.
Self-collection has also been validated in younger populations. A study in adolescents found adequate specimen collection in over 99% of self-collected rectal swabs, confirming that the technique does not require clinical training to perform correctly.11PLOS ONE. Adolescents may accurately self-collect pharyngeal and rectal clinical specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae infection These findings open the door to mail-in testing kits and telehealth-based screening that could dramatically improve detection rates, especially in communities where in-person sexual health services are limited.
Treatment and the Resistance Problem
Ceftriaxone, a third-generation cephalosporin given as a single intramuscular injection, is the standard treatment for rectal gonorrhea. A systematic review and meta-analysis of randomized controlled trials found that ceftriaxone monotherapy cleared rectal gonorrhea in 100% of cases across doses ranging from 125 mg to 500 mg.12Journal of Antimicrobial Chemotherapy. Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials Most current guidelines recommend a 500 mg dose to maintain a safety margin against emerging resistance.
The efficacy of ceftriaxone is reassuring, but the broader story of gonococcal antibiotic resistance is not. N. gonorrhoeae has a remarkable ability to develop resistance to nearly every antibiotic class thrown at it. An Australian surveillance study spanning a decade found that by 2006, roughly half of gonococci in large urban centers were resistant to penicillin, ciprofloxacin, or both.13Journal of Antimicrobial Chemotherapy. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006 Ciprofloxacin resistance emerged even in areas where the drug had barely been used, suggesting that resistant strains circulate independently of local prescribing patterns.
What about alternatives to ceftriaxone? The G-TOG trial tested gentamicin head-to-head against ceftriaxone and found it fell short. While gentamicin cleared genital infections at a rate of 94%, its rectal clearance rate was only 90%, compared to 98% for ceftriaxone.14PubMed Central. Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT The study could not demonstrate that gentamicin was equivalent to ceftriaxone. Pharyngeal clearance was even worse, at 80% versus 96%. These results highlight that the rectum and throat are harder sites to treat than the genitals, and they reinforce why maintaining ceftriaxone susceptibility matters so much.
The HIV Connection
Rectal gonorrhea and HIV have a two-way relationship that matters for prevention. Rectal gonorrhea increases the risk of acquiring HIV independent of sexual behavior. A study found that rectal gonorrhea and chlamydia raise the risk of a new HIV diagnosis through biological mechanisms, primarily by increasing the number of immune cells (the very cells HIV targets) at the site of exposure and causing mucosal disruption that makes it easier for the virus to enter.15PubMed Central. New HIV Diagnosis Independently Associated with Rectal Gonorrhea and Chlamydia in Men who have sex with Men
For people already living with HIV who are on effective antiretroviral therapy, the picture is more nuanced. One study found that asymptomatic rectal gonorrhea and chlamydia did not increase rectal HIV viral load in people who were fully suppressed on treatment.16PubMed. Impact of rectal gonorrhoea and chlamydia on HIV viral load in the rectum: potential significance for onward transmission In other words, for someone whose HIV is well controlled, having rectal gonorrhea doesn’t appear to make them more infectious to partners via rectal HIV shedding. This doesn’t diminish the importance of treating the gonorrhea, but it provides some reassurance about onward HIV transmission in the context of effective antiretroviral therapy.
Syphilis co-infection is also more common in this population. Among men who have sex with men who tested positive for rectal gonorrhea or chlamydia, about 24% had current or past syphilis, compared to 13% among those who tested negative.17PubMed Central. Syphilis Testing among Men Who Have Had Rectal Gonorrhea and Chlamydia Tests, United States This overlap makes a strong case for comprehensive STI screening whenever rectal gonorrhea is diagnosed, rather than treating it in isolation.
Screening Gaps in the Real World
Guidelines recommend regular three-site STI screening (genital, rectal, and pharyngeal) for men who have sex with men, especially those on HIV pre-exposure prophylaxis. The reality falls short. A U.S. survey found that while 87% of PrEP users reported consistent screening by blood sample and 78% by urine or urethral swab, only 57% reported consistent rectal swab screening during PrEP care.18Clinical Infectious Diseases. Gaps in Sexually Transmitted Infection Screening Among Men who Have Sex with Men in Pre-exposure Prophylaxis Care in the United States Geographic disparities compound the problem: PrEP users in the U.S. Southeast were significantly less likely to receive consistent rectal screening than those elsewhere.
Given that most rectal gonorrhea is asymptomatic, these screening gaps mean a substantial number of infections are going undiagnosed. Every missed case is a potential source of onward transmission and a missed opportunity to reduce HIV risk. The availability of validated self-swab methods could help close this gap, but uptake depends on awareness among both patients and providers.
Doxycycline as Post-Exposure Prevention
One of the most significant developments in STI prevention in recent years is doxycycline post-exposure prophylaxis, commonly called doxy-PEP. The idea is simple: take 200 mg of doxycycline within 72 hours after condomless sex to prevent bacterial STIs. A landmark trial published in the New England Journal of Medicine found that doxy-PEP reduced gonorrhea incidence by about 55% in people on PrEP and by a similar margin in people living with HIV.19PubMed Central. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections For chlamydia and syphilis, the reductions were even more dramatic, ranging from roughly 75% to nearly 90%.
A separate randomized trial confirmed the overall benefit, finding that STIs were present in 12% of person-quarters in the doxy-PEP group compared to about 31% in standard care, representing a relative risk reduction of about 61%.20The Lancet Infectious Diseases. Doxycycline post-exposure prophylaxis for the prevention of bacterial sexually transmitted infections: a randomized trial
The protection against gonorrhea is real but less complete than against chlamydia or syphilis. This makes sense: gonococci already carry high levels of tetracycline resistance in many populations, so doxycycline (a tetracycline) has a harder time killing them. There are also concerns that widespread doxy-PEP use could accelerate resistance in gonococci and other bacteria, including commensal organisms in the gut and throat. This is an active area of monitoring, and the long-term trade-offs between preventing current infections and selecting for resistant organisms remain an open question.
How the Bacterium Interacts With Rectal Tissue
N. gonorrhoeae has a sophisticated toolkit for colonizing mucosal surfaces. Laboratory work using polarized epithelial cells has revealed that the bacterium’s opacity proteins, particularly OpaH, play a key role in how it adheres to and aggregates on the surface of host cells. Bacteria expressing Opa proteins form large clumps on the cell surface and recruit specific host receptors called CEACAMs to their attachment sites. Paradoxically, this firm attachment actually slows the bacterium’s ability to cross the epithelial barrier. In experiments, gonococci lacking Opa proteins crossed the cell layer in much greater numbers, reaching the other side roughly 100 times faster than Opa-expressing bacteria within six hours.21PLoS ONE. Expression of Opacity Proteins Interferes with the Transmigration of Neisseria gonorrhoeae across Polarized Epithelial Cells Even when Opa-expressing bacteria were used to start the infection, every bacterium that made it through to the other side had switched off Opa expression.
What this means in the rectal setting is that the gonococcus can toggle between two strategies: gripping tightly to the surface (causing local inflammation and symptoms) and slipping between cells to invade deeper tissue. This phase variation, the bacterium’s ability to switch surface proteins on and off, helps explain why the organism is so successful at establishing persistent infections and why it can produce such a range of clinical presentations from completely silent to acutely symptomatic.
Rectal Microbiome Shifts During Infection
Rectal gonorrhea doesn’t exist in a vacuum. The infection alters the microbial community of the rectum in measurable ways. A study comparing the rectal microbiomes of people with and without chlamydia or gonorrhea found that infected individuals had significantly higher microbial diversity than uninfected ones. The relative abundance of Neisseria and Chlamydia species was predictably elevated in infected samples, while Escherichia species were about three times more abundant in uninfected individuals.22PLoS ONE. Chlamydia trachomatis and Neisseria gonorrhoeae rectal infections: Interplay between rectal microbiome, HPV infection and Torquetenovirus
A prospective cohort study tracking microbiota changes over time in men who have sex with men noted that the relationship between N. gonorrhoeae colonization and rectal microbiome composition remains unclear, with site-specific dynamics differing between the rectum and the throat.23PubMed Central. Changes in anorectal and oropharyngeal microbiota following infection of Neisseria gonorrhoeae in men who have sex with men: a prospective cohort study Whether these microbiome changes are a cause or consequence of infection, and whether they influence susceptibility to reinfection, are questions researchers are still working to answer. It’s an area where the science is genuinely in its early stages.
Vaccine Prospects
There is no licensed vaccine against gonorrhea, but one intriguing lead has emerged from an unexpected source. The MenB-4C vaccine, designed to protect against meningococcal disease caused by Neisseria meningitidis serogroup B, shares enough surface protein similarity with N. gonorrhoeae to offer some cross-protection. A systematic review and meta-analysis assessed the published evidence on MenB-4C vaccine effectiveness against gonorrhea.24The Journal of Infectious Diseases. Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis While the protection is partial and the data are still accumulating, the finding has generated considerable excitement because any level of vaccine-induced protection against gonorrhea would be a first.
For rectal gonorrhea specifically, a vaccine could be transformative. Given the high rates of asymptomatic infection, the screening gaps that exist even in well-resourced healthcare settings, and the relentless march of antibiotic resistance, a preventive approach that doesn’t depend on detecting and treating every individual case would change the epidemiological equation. Whether the meningococcal vaccine strategy or a purpose-built gonorrhea vaccine reaches that goal remains to be seen, but the biological plausibility is there, and trials are underway.